Sadiya S. Khan, MD, MS; Hongyan Ning, MD, MS; John T. Wilkins, MD, MS; et al.
free access
JAMA Cardiol. 2018;3(4):280-287. doi:10.1001/jamacardio.2018.0022
This population-based study calculates lifetime risk estimates for incident cardiovascular disease and subtypes of cardiovascular disease and estimates years lived with and without cardiovascular disease by weight status.
Apostolos Tsimploulis, MD; Phillip H. Lam, MD; Cherinne Arundel, MD; et al.
free access
JAMA Cardiol. 2018;3(4):288-297. doi:10.1001/jamacardio.2017.5365
This observational study examines the mortality of patients with systolic blood pressure and other outcomes in heart failure with preserved ejection fraction.
Rebecca R. Vanderpool, PhD; Melissa Saul, MS; Mehdi Nouraie, MD, PhD; et al.
free access
JAMA Cardiol. 2018;3(4):298-306. doi:10.1001/jamacardio.2018.0128
This cohort study identifies the hemodynamic characteristics and outcomes of pulmonary hypertension associated with heart failure with preserved ejection fraction.
Saurabh Rajpal, MD; Laith Alshawabkeh, MD, MSc; Nureddin Almaddah, MD; et al.
free access
JAMA Cardiol. 2018;3(4):308-316. doi:10.1001/jamacardio.2018.0125
This study assesses the prevalence, risk factors, and prognostic implications of albuminuria in adults with congenital heart disease.
Bhupesh Panwar, MD; Suzanne E. Judd, PhD; Virginia G. Wadley, PhD; et al.
free access
JAMA Cardiol. 2018;3(4):318-325. doi:10.1001/jamacardio.2018.0139
This study determines the association of plasma fibroblast growth factor 23 concentrations with incident coronary heart disease and whether this association differs by race, sex, or chronic kidney disease status.
Ashwin Prakash, MD; Leslie B. Gordon, MD, PhD; Monica E. Kleinman, MD; et al.
free access
JAMA Cardiol. 2018;3(4):326-334. doi:10.1001/jamacardio.2017.5235
This case-series study examines the course of appearance of cardiac abnormalities in patients with Hutchinson-Gilford progeria syndrome to identify meaningful cardiac end points to use in future clinical trials.